Announcements Trials
Browse Landscape

Phase

Phase 2 5Phase NA 2Phase 4 1Phase 2/3 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 2Other hematologic neoplasm 1Myeloid 1Genitourinary 1Classical hematology 1

Conditions

Prostatic Neoplasms 1

Interventions

Gemcitabine 9Docetaxel 8Androgen Antagonists 7acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 6Magnetic Resonance Spectroscopy 6gallium 68 PSMA-11 5Prednisone 5Leuprolide 5Goserelin 5Cisplatin 5enzalutamide 4bicalutamide 4Triptorelin Pamoate 4Radiosurgery 4Carboplatin 42-(3-(1-carboxy-5-((6-fluoropyridine-3-carbonyl)amino)pentyl)ureido)pentanedioic acid 4luprolide acetate gel depot 3Flutamide 3Celecoxib 3valrubicin 2pembrolizumab 2nilutamide 2cabazitaxel 2abiraterone 2Zoledronic Acid 2Vinblastine 2Specimen Handling 2Radiotherapy, Intensity-Modulated 2Radiotherapy 2Nivolumab 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2/3 × Tacrolimus × Genitourinary × Clear all
NCT00922129 2014-01-14

Effectiveness of Conversion to Sirolimus Versus Calcineurin Inhibitor (CNI) Reduction in Renal Transplant Patients With Prostate Cancer

St. Joseph's Healthcare Hamilton

Phase 2/3 Withdrawn
Genitourinary

Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡